V 565

Drug Profile

V 565

Alternative Names: V565

Latest Information Update: 13 Jan 2017

Price : $50

At a glance

  • Originator VHsquared
  • Class Antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Crohn's disease
  • Clinical Phase Unknown Inflammatory bowel diseases

Most Recent Events

  • 08 Dec 2016 Clinical trials in Inflammatory bowel disease in United Kingdom (PO)
  • 06 Dec 2016 VHSquared plans a phase II trial for Crohn's disease in USA, United Kingdom, Czech Republic and Germany (NCT02976129)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top